key: cord-0058108-0noiqj63 authors: Guagliumi, Giulio; Pellegrini, Dario; Finn, Aloke; Gerevini, Simonetta title: Cardiac Involvement in COVID-19 Infection date: 2021-03-18 journal: Neuroimaging of Covid-19 DOI: 10.1007/978-3-030-67521-9_8 sha: caafb5980063cf6d7579fa88498176ab0ededf1f doc_id: 58108 cord_uid: 0noiqj63 COVID-19 infection appeared to be associated with increased risk of thrombotic events, ranging from microvascular thrombosis to venous thromboembolic disease (including deep vein thrombosis and pulmonary embolism), and stroke [1]. COVID-19 infection appeared to be associated with increased risk of thrombotic events, ranging from microvascular thrombosis to venous thromboembolic disease (including deep vein thrombosis and pulmonary embolism), and stroke [1] . Such thrombotic manifestations could be associated with multiorgan failure and increased mortality observed in a significant portion of patients, and suggest the presence of an underlying hypercoagulable status. Causes are still unclear, although cytokine storm and hyperactivation of complement-mediated immune response and endothelial damage have been proposed as possible mechanisms. Indeed, SARS-CoV-2 may be able to invade endothelial cells through angiotensin-converting enzyme 2 (ACE-2) and TMPRSS2 (transmembrane serine protease 2), which are highly expressed on the endothelial cell surface, and lead to inflammation in the endothelium [2] . Lymphocytic endotheliitis with recruitment of inflammatory cells was observed in the lungs, heart, liver and kidneys [2] on histological assessment, although prevalence of infection and viral-related extrapulmonary damage showed significant variability across published reports [3] . Systemic anticoagulation was associated with prolonged survival in patients hospitalized with COVID-19 [4] although uncertainty persists on best drug and dose choice, both in terms of efficacy and safety. A broad spectrum of cardiovascular disorders have been reported in the setting of SARS-CoV-2, including acute coronary syndromes, myocardial injury and arrhythmias [5] [6] [7] . Acute myocardial injury, as evidenced by elevated levels of cardiac biomarkers or electrocardiogram abnormalities, was observed in 7-20% of pts. Children with COVID-19 have also been reported to develop hyperinflammatory shock with features similar to Kawasaki disease, including cardiac dysfunction and coronary vessel abnormalities. Direct viral invasion [8] [9] [10] [11] and damage stemming from hyperimmune systemic reaction [9, [12] [13] [14] have been advanced as possible mechanisms, as inflammation and myocardial localization of coronavirus particles were described at endomyocardial biopsy. However, these findings suffered from high variability in published literature [15] . Acute coronary syndromes may be triggered different mechanisms, including the aforementioned hypercoagulable status, plaque rupture or spasm of epicardial coronary arteries [16, 17] . Recently, the pathologic finding of extensive thrombosis in the cardiac microcirculation has been described in a case of a young woman dying of ST-segment elevation acute myocardial infarction (STEMI), with normal coronary angiography [18] . No specific exams can detect microthrombi, so this phenomenon may explain the high number of reported acute coronary syndromes or acute myocardial dysfunction without a clear culprit lesion at angiography, which were at first deemed to be related to myocarditis. Finally, as similar thrombotic formations were reported also in the vascular bed of other extracardiac organs, this mechanism may be a specific feature of COVID-19, and may underlie the high rate of multiorgan failure. Hypercoagulable state, endothelial damage, cytokine storm and hyperactivation of macrophages have been postulated as possible mechanisms, but additional evidence is needed (Fig. 8.1 ) [19] . COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives Covid-19 endothelitis COVID-19-Associated coagulopathy: an exacerbated immunothrombosis response Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19 Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Potential effects of coronaviruses on the cardiovascular system: a review Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study Myocardial localization of coronavirus in COVID-19 cardiogenic shock The trinity of COVID-19: immunity, inflammation and intervention Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic Coronavirus disease 2019 (COVID-19) and cardiovascular disease A current review of COVID-19 for the cardiovascular specialist Inflammation and its resolution as determinants of acute coronary syndromes Mechanisms of plaque formation and rupture Microthrombi and ST-segment-elevation myocardial infarction in COVID-19 Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19